Alimentazione e trattamento con Tamoxifene

 

Il tamoxifene (Nolvadex) è una terapia ormonale  efficace nella prevenzione e nel trattamento del carcinoma mammario positivo ai recettori per gli estrogeni (ER +). Da numerosi studi scientifici è stato valutato che le donne che assumono i trattamenti antiestrogeni prescritti presentano tassi di recidiva  e sopravvivenza migliori rispetto alle donne che non assumono la terapia ormonale. Ci sono alcuni alimenti che sembrano migliorare l'efficacia del trattamento 

con tamoxifene e altri che lo riducono.

Il tamoxifene è associato ad un rischio più elevato di carcinoma dell'endometrio per le donne che non hanno avuto un'isterectomia e un rischio maggiore di sviluppare problemi di coagulazione , tra gli altri effetti collaterali. Tuttavia, ci sono alcuni alimenti che possono proteggere dal cancro dell'endometrio senza interferire con l'efficacia del tamoxifene.

Alcuni antidepressivi selettivi dell'inibitore del reuptake della serotonina (SSRI) come Paxil (paroxetina) e Prozac (fluoxetina), così come l'antagonista della serotonina e l'inibitore del reuptake Oleptro (trazodone), possono interferire con il trattamento con tamoxifene in alcune donne. Tuttavia, non tutti gli studi hanno trovato un collegamento. L'esposizione alla luce notturna sopprime la produzione di melatonina , che a sua volta può portare alla resistenza al tamoxifene . L'uso regolare di aspirina sembra migliorare l'efficacia del tamoxifene. Prove preliminari suggeriscono che l'uso a lungo termine di tamoxifene potrebbe aumentare il rischio di degenerazione maculare.

Tamoxifene e peso corporeo

Uno studio ha riportato che le secrezioni da cellule staminali adipose di donne obese potrebbero essere in grado di contrastare gli effetti del trattamento con il tamoxifene, suggerendo che il sovrappeso potrebbe contribuire alla resistenza al tamoxifene. Inoltre, è stato riscontrato che l' aumento di peso , che è comune durante il trattamento con tamoxifene, è associato a prognosi meno favorevole.

Tamoxifene e colesterolo

Esistono prove del fatto che le cellule tumorali al seno che non rispondono al tamoxifene potrebbero utilizzare il colesterolo per proteggersi dal farmaco. Sebbene non sia chiaro che la riduzione del colesterolo alimentare influirebbe notevolmente su questo processo, può avere senso per i pazienti con carcinoma mammario in trattamento con tamoxifene ridurre il loro colesterolo a livelli normali.

Il tamoxifene potrebbe aumentare il rischio di diabete di tipo 2

È stato riferito che l'uso di tamoxifene nel trattamento per carcinoma mammario è associato ad un aumentato rischio di diabete di tipo 2 . Questo rischio può essere più elevato nelle donne che hanno altri fattori di rischio per il diabete.

La vitamina D e altri micronutrienti influenzano il trattamento con tamoxifene

La vitamina D ha dimostrato di inibire la crescita delle cellule cancerose della mammella resistenti al tamoxifene in laboratorio e si è scoperto che il resveratrolo riduce la loro proliferazione. Il selenio e l'acido linoleico coniugato ( CLA ) possono migliorare l'efficacia del tamoxifene, mentre la vitamina C , la vitamina E , il trifoglio rosso e la tangeretina hanno dimostrato di ridurlo. Inoltre, le verdure di brassica contengono sulforaphane , un inibitore dell'istone deacetylase (HDAC) che può causare un aumento sinergico di apoptosi e morte cellulare in combinazione con tamoxifene

Alimenti che aumentano l'efficacia del trattamento con tamoxifene

È stato riscontrato che i seguenti alimenti (o componenti principali) aumentano gli effetti del tamoxifene nel trattamento del cancro al seno .

salmerino alpino carciofi Rucola Peperoni Cumino nero Pepe nero More Mirtilli e mirtilli Bok Choy Broccoli e germogli di broccoli cavoletti di Bruxelles Grano saraceno Zucca torta Cavolo Cantalupo Carote Cavolfiore Cuori di sedano e sedano Ciliegie, soprattutto acide o crostate Pollo, fegati organici , ma non fegati o pelle di pollo Erba cipollina coriandolo caffè Verdure verdi Mirtilli e mirtilli rossi Ribes, nero Semi di lino e olio di semi di lino Aglio Fresco Zenzero Uva e succo d'uva, rosso

Tè verde aringa Rafano e wasabi Peperoncino cavolo kefir trota di lago Limoni Limes Sgombro Funghi Mostarda Senape Olio d'oliva, extravergine e olive Cipolle, verdi o rosse Prezzemolo Melograni e succo di melograno zucche Riso, marrone, nero o viola Salmone, selvaggio sardine Alghe, marrone Fragole Pomodori Turchia, biologica Rape e cime di rapa Noci e olio di noci Crescione e crescione del giardino Zucchine

Alimenti e integratori che non devono essere utilizzati durante il trattamento con tamoxifene

I seguenti alimenti (o componenti principali) e integratoripotrebbero  ridurre l'efficacia del tamoxifene e dovrebbero essere evitati durante il trattamento con tamoxifene:

alcool Integratori di apigenina Succo di clementina Supplementi di curcumina o curcuma Integratori di genisteina, daidzeina o equolo Integratori Goldenseal Pompelmo Dieta ricca di proteine TOS, combinato (estrogeno più progestinico) Supplementi I3C o DIM Integratori di L-carnitina Scorza di arancia o mandarino - si trova nel tè all'arancia, marmellata di arance, pollo all'arancia di Szechuan

Integratori di trifoglio rosso carne rossa semi di sesamo Integratori Si-Wu-Tang Integratori a calotta cranica Alimenti a base di soia, in particolare soia , isolato di proteine ​​di soia , pasta di soia Supplementi di iperico Integratori di Suan-Tsao-Ren-Tang Integratori di mandarino Integratori di vitamina C. Integratori di vitamina E.

Esistono numerosi studi su cellule e animali che dimostrano che la curcumina presente nella curcuma può migliorare l'efficacia del tamoxifene. Tuttavia, i supplementi di curcumina possono interferire con il trattamento con tamoxifene perché potenzialmente forniscono curcumina a dosi farmacologiche (piuttosto che a dosi chemiopreventive). Vedere Tamoxifene e legame con curcumina all'albumina sierica nell'elenco di studio di seguito.

Vi sono anche alcune prove che l'esposizione al bisfenolo A ( BPA ), ai parabeni o al fumo di sigaretta potrebbe interferire con l'efficacia del trattamento con tamoxifene.

Alimenti che riducono il rischio di cancro dell'endometrio

I seguenti alimenti (o componenti principali) sono stati associati a un minor rischio di carcinoma dell'endometrio, proteggendo al contempo dal carcinoma mammario:

Rucola Peperoni Pepe nero Tè nero Noci brasiliane broccoli cavoletti di Bruxelles Carote Ciliegie acide Verdure verdi Aglio Tè verde aringa Miele, trasformato minimamente * Peperoncino cavolo trota di lago porri

Lattuga, Roma Sgombro Senape Cipolle Melograni e succo di melograno zucche Lamponi, in particolare neri Zafferano Salmone, selvaggio sardine Alga marina Pomodori Cime di rapa olio di noci Crescione Anguria Zucchine

'*Con moderazione.

Alimenti che aumentano il rischio di cancro dell'endometrio

Gli alimenti e gli integratori elencati di seguito sono stati associati ad un aumentato rischio di cancro endometriale. Dolci e altri alimenti ad alto indice glicemico , nonché grassi animali, hanno dimostrato di aumentare il rischio. L'esposizione al cadmio è associata ad un aumentato rischio. Gli alimenti ad alto contenuto di acrilamide , come patatine fritte, cereali, patatine fritte, patate e prodotti da forno, hanno anche dimostrato di aumentare il rischio di cancro dell'endometrio.

Bacon

Manzo

Pane, baguette e cornetti

Burro

Formaggio, grasso intero

Biscotti, caramelle e torte

Plantani maturi fritti

Genistein e daidzein

muesli

Latte (intero)

Patate, patatine e patatine fritte

mollusco

zucchero

Dessert Dolci

Cereali per la colazione zuccherati

Carne ben cotta o fritta

riso bianco

È stato anche riscontrato che l'uso a lungo termine di coperte elettriche è associato ad un aumentato rischio di cancro endometriale e deve essere evitato.

È stato riportato che gli alimenti seguenti riducono la probabilità di coaguli di sangue proteggendo o essendo neutri rispetto al rischio di cancro al seno.

Alimenti che riducono il colesterolo

I seguenti alimenti hanno dimostrato di migliorare il profilo del colesterolo e allo stesso tempo di proteggere dal cancro al seno:

Mele carciofi Peperoni mirtilli broccoli riso integrale cavoletti di Bruxelles Grano saraceno Cavolo Carote Sedano ciliegie Mirtilli Cetrioli

Fagioli secchi Pesce grasso Olio di semi di lino Uva verdura Rafano Peperoncino cavolo Lattuga Funghi Olio d'oliva Melograni e succo di melograno Alga marina Noci e olio di noci

Alimenti che aumentano il colesterolo

I seguenti alimenti hanno dimostrato di peggiorare il profilo del colesterolo:

Bacon

Manzo

Burro

Caviale

Formaggio

caffè

Latte intero o panna

Olio parzialmente idrogenato

Maiale

Commenti aggiuntivi

Il tamoxifene è un modulatore selettivo del recettore degli estrogeni (SERM), che regola ER verso il basso ma non ERβ (al contrario, inibitori dell'aromatasi come Arimidex up-regola ERβ). Il tamoxifene è efficace nella prevenzione del carcinoma mammario ER + e nel trattamento delle fasi iniziali, ma questa efficacia può diminuire nel tempo se il tumore progredisce nonostante il trattamento. Inoltre, il tamoxifene non previene il carcinoma mammario ER. Le donne che sviluppano un carcinoma mammario primario o una recidiva nonostante il trattamento con tamoxifene hanno un rischio maggiore di sviluppare un carcinoma mammario ER, una malattia più aggressiva di ER +.

Pertanto, è importante che le donne in trattamento con tamoxifene mangino un'ampia varietà di alimenti dalla  lista raccomandata e limitino o evitino quelli nella  lista di evitare , oltre a prestare particolare attenzione agli alimenti sopra elencati. Si prega di consultare il nostro articolo su come ottimizzare la dieta del cancro al seno per informazioni su cosa mangiare durante tutte le fasi del trattamento e del recupero.

             lavori Scientifici

• Characteristics of adverse events of endocrine therapies among older patients with breast cancer
• 17β-estradiol at low concentrations attenuates the efficacy of tamoxifen in breast cancer therapy
• Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer
• Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
• Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement
• Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan
• Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK
• Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
• Clinicopathologic features of hormone receptor positive breast cancer patients with late recurrence
• LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer
• Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
• The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer
• SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma
• Estrogen-based hormone replacement [HRT] therapy is substantially more effective than tamoxifen in reducing breast cancer mortality and breast cancer case fatality ratio: Emergence of a new paradigm
• Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
• Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer
• Effects of a soy isoflavone in breast cancer treatment
• Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women
• Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis
• Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors
• Soy foods might weaken the sensitivity of tamoxifen in pre-menopausal patients with Lumina A subtypes of breast cancer
• CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy
• The modulatory role of low concentrations of bisphenol A on tamoxifen-induced proliferation and apoptosis in breast cancer cells
• Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients
• Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor Positive Breast Cancer
• A Comparative Study on Viability of Mcf-7 Human Breast Cancer Cell Lines Using Piperine and Tamoxifen - An In Vitro Study with A Novel Mishmash
• Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
• Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review
• Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure
• Combinatorial anti-proliferative effects of tamoxifen and naringenin: The role of four estrogen receptor subtypes
• Meta‐analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy
• Impact of curcumin with and without (+/-) piperine on tamoxifen exposure
• Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer
• Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy
• Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
• Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study
• Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy
• Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer
• Breast cancer survival, survival disparities, and guideline-based treatment
• Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
• Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database
• Breast cancer stem-like cells are sensitized to tamoxifen induction of self-renewal inhibition with enforced Let-7c dependent on Wnt blocking
• Adipocyte/breast cancer cell crosstalk in obesity interferes with the anti-proliferative efficacy of tamoxifen
• Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells
• Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients
• Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis
• Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
• Tamoxifen Use Correlates with Increased Risk of the First Episode of Ischemic Cerebrovascular Disease in Older Women with Breast Cancer: A Case-Control Study in Taiwan
• 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
• Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan
• Synthesis and Characterization of PLGA-PEG Thymoquinone Nanoparticle and its Cytotoxicity Effects in Tamoxifen-resistant Breast Cancer Cells
• Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population
• Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
• Nationwide Case-Control Study Examining the Association between Tamoxifen Use and Alzheimer’s Disease in Aged Women with Breast Cancer in Taiwan
• Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients
• Long-Term Follow-Up of the Intergroup Exemestane Study
• Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy
• Anti-cancer potential of a mix of natural extracts of turmeric, ginger and garlic: A cell-based study
• Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells
• Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
• Mammographic density reduction as a prognostic marker for postmenopausal breast cancer; results using a joint longitudinal-survival modelling approach
• Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death
• Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study
• The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment
• Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells
• Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients
• Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: A systematic review and meta-analysis
• Naringenin Inhibits Proliferation and Survival of Tamoxifen‐Resistant Breast Cancer Cells
• Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
• Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin
• Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo
• Aloe-Emodin Enhances Tamoxifen Cytotoxicity by Suppressing Ras/ERK and PI3K/mTOR in Breast Cancer Cells
• Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
• Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity
• Antihyperglycemic Effect of Quercetin in Ovariectomized Rats Treated with Tamoxifen
• An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome
• Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
• Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer; a Prospective Multicenter Study
• Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630
• Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy
• Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study
• Estrogens - the Saviors of Cognitive Function?
• Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting
• Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
• The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer
• Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis
• Estrogen Receptor Activation by Tobacco Smoke Condensate in Hormonal Therapy-Resistant Breast Cancer Cells
• Diverse Effects of the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), in Combination with Tamoxifen Citrate and Doxorubicin in MCF-7 Breast Cancer Cells
• Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting
• Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer
• Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERa positive breast cancer by up-regulation of ERβ
• Acquired tamoxifen resistance sensitises breast cancer cells to bisphosphonates
• The impact of tamoxifen brand switch on side effects and patient compliance in hormone receptor positive breast cancer patients
• Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
• Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
• Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes
• Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients
• Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14
• Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment
• Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer
• Defining the implications of sugar derived metabolites (AGEs) to tamoxifen resistance and breast cancer disparity: Is it a question of lifestyle?
• Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
• Could Caffeic Acid Phenethyl Ester Expand the Antitumor Effect of Tamoxifen in Breast Carcinoma?
• Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications
• Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials
• Current issues in adjuvant hormonal therapy for early breast cancer
• Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
• Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen
• Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
• The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling
• Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
• MicroRNA-206, Let-7 and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer
• Effects of Aqueous Extracts of Chicory and Milk Thistle on Serum Concentrations of Copper, Zinc, and Manganese in Tamoxifen-Treated Rats
• Male breast cancer is not congruent with the female disease
• Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical Study
• The selective estrogen receptor modulators in breast cancer prevention
• Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
• Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
• Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats
• Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy
• Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells
• Hyperglycaemia-induced chemo-resistance in breast cancer cells: role of the estrogen receptor
• Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer Survivors
• The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review
• Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity
• Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells
• In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism
• Augmentation of oxidative stress-induced apoptosis in MCF7 cells by ascorbate-tamoxifen and/or ascorbate-juglone treatments
• Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer
• Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells
• Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients
• Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
• Effects of exercise training together with tamoxifen in reducing mammary tumor burden in mice: Possible underlying pathway of miR-21
• Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
• Combination of siRNA-directed gene silencing with epigallocatechin-3-gallate (EGCG) reverses drug resistance in human breast cancer cells
• Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
• mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells
• Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells
• Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice
• Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ
• Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients
• Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors
• Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants
• CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
• Tamoxifen acceptance by DCIS patients and effect on subsequent ipsilateral and contralateral breast events
• Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors
• How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?
• Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer
• Long-term Use of Tamoxifen Reduces the Risk of Dementia: A Nationwide Population-Based Cohort Study
• Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer
• Tamoxifen treatment and the reduced risk of hyperlipidemia in Asian breast cancer patients: A population-based cohort study
• Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism
• Prognostic Significance of Mammographic Density Change after Initiation of Tamoxifen for ER-Positive Breast Cancer
• Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review
• Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis
• Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort
• Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer
• Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer
• Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes
• Decision-making impairments in breast cancer patients treated with tamoxifen
• Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth
• IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer
• Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.
• A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells
• Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
• Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer
• 1α,25-Dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells
• Primary endocrine therapy as a treatment for older women with operable breast cancer - A comparison of randomised controlled trial and cohort study findings
• Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients
• Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response
• Adjuvant Tamoxifen Influences the Lipid Profile in Breast Cancer Patients
• Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Tamoxifen Use: a Population Based Study
• Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials
• Modulatory effects of l-carnitine on tamoxifen toxicity and oncolytic activity In vivo study
• Fucoidan extract enhances the anti-cancer activity of chemotherapeutic agents in breast cancer cells
• Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen
• Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
• Alopecia With Endocrine Therapies in Patients With Cancer
• A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer
• Menopausal Symptoms among Breast Cancer Patients: A Potential Indicator of Favorable Prognosis
• Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
• Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment
• Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness--a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
• MEK1/2 Inhibition Suppresses Tamoxifen Toxicity on CNS Glial Progenitor Cells
• The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
• Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer
• Resveratrol Sensitizes Tamoxifen in Antiestrogen-Resistant Breast Cancer Cells with Epithelial-Mesenchymal Transition Features
• Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials
• The Relative Benefits of Tamoxifen in Older Women with T1 Early-Stage Breast Cancer Treated with Breast-Conserving Surgery and Radiation Therapy
• Modeling the Effectiveness of Initial Management Strategies for Ductal Carcinoma In Situ
• CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
• Initiation of Aspirin Therapy Modulates Angiogenic Protein Levels in Women with Breast Cancer Receiving Tamoxifen Therapy
• Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells
• Fracture Risk in Older, Long-Term Survivors of Early-Stage Breast Cancer
• Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression
• Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations
• Mammographic Density Reduction Is a Prognostic Marker of Response to Adjuvant Tamoxifen Therapy in Postmenopausal Patients With Breast Cancer
• Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis
• Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model
• Breast Cancer and Obesity: In Vitro Interferences between Adipokines and Proangiogenic Features and/or Antitumor Therapies?
• Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
• Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
• Comparison of Tamoxifen with Edible Seaweed (Eucheuma cottonii L.) Extract in Suppressing Breast Tumor
• Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women
• Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status
• Tualang Honey Promotes Apoptotic Cell Death Induced by Tamoxifen in Breast Cancer Cell Lines
• Pharmacokinetic Drug Interactions between Ondansetron and Tamoxifen in Female Sprague-Dawley Rats with DMBA-induced Mammary Tumor
• Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
• The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
• CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
• Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study
• Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
• Tamoxifen and Curcumin Binding to Serum Albumin. Spectroscopic Study
• Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer
• Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
• Fish Oil Alters Tamoxifen-Modulated Expression of mRNAs That Encode Genes Related to Differentiation, Proliferation, Metastasis, and Immune Response in Rat Mammary Tumors
• Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer
• Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study
• Estradiol, Tamoxifen, and Flaxseed Alter IL-1β and IL-1Ra Levels in Normal Human Breast Tissue in Vivo
• Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition
• Hair shaft abnormalities after chemotherapy and tamoxifen therapy in breast cancer patients evaluated by optical coherence tomography
• Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer
• Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
• Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone
• Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer
• Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer
• Surgery for widely disseminated breast cancer: prolonged control by excision of metastases
• Second malignancies after breast cancer: the impact of different treatment modalities
• Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
• Combined treatment of breast cancer cells with epigallocatechin gallate (EGCG) and Tamoxifen delays cell-growth in long-term culture: Implications for recurrent breast cancer
• Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
• Molecular Pathways: Digoxin use and the estrogen-sensitive cancers: risks and possible therapeutic implications
• Influence of Tangeretin on Tamoxifen's Therapeutic Benefit in Mammary Cancer
• Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
• A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up
• Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice
• Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study
• Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator
• Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer
• Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation
• Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells
• Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study
• Reduced Bioavailability of Tamoxifen and its Metabolite 4-Hydroxytamoxifen After Oral Administration with Biochanin A (an Isoflavone) in Rats
• Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle
• Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers
• Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
• Association between tamoxifen treatment and diabetes
• Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging
• Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis
• Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark
• Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation
• CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract
• Mammary Gland Density Predicts the Cancer Inhibitory Activity of the N-3 to N-6 Ratio of Dietary Fat
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
• Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
• Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells
• Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells
• Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer
• An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs)
• Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial
• Bisphenol A Increases Mammary Cancer Risk in Two Distinct Mouse Models of Breast Cancer
• Transcriptomic changes in tamoxifen-treated mammary tumors in Sprague-Dawley rats fed with omega-3 or omega-6 rich diets
• Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
• Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells
• Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
• Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
• Dual Estrogen Effects on Breast Cancer: Endogenous Estrogen Stimulates, Exogenous Estrogen Protects. Further Investigation of Estrogen Chemoprevention Is Warranted
• Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
• Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro
• Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen
• Improvement in self-reported physical health predicts longer survival among women with a history of breast cancer
• Risk of second breast cancer according to estrogen receptor status and family history
• Sexual Function after Breast Cancer
• Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve
• Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
• Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women's Healthy Eating and Living Study
• Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
• Breast cancer in the very elderly: Staging, treatment, and outcomes in patients over age 80
• Primary endocrine therapy for early operable primary breast cancer in elderly women: Survival analysis of a large series from a single institution
• Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO
• Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial
• Effects of dietary omega-3 and omega-6 in the prevention of rat mammary cancer with tamoxifen
• (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line
• Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
• Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
• Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
• Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes
• Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users
• Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis
• Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy
• Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
• Soy Food Intake and Breast Cancer Survival
• Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis
• Breast cancer recurrence risk in relation to antidepressant use after diagnosis
• HDAC inhibitors trigger the autophagic switch from prosurvival to prodeath in tamoxifen-treated breast cancer cells
• Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells
• Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis
• Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma
• Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol
• Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment
• The Effect of the Phytoestrogens Genistein, Daidzein, and Equol on the Growth of Tamoxifen-Resistant T47D/PKCα
• Phytoestrogens and breast cancer: a complex story
• EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein
• Chemopreventive effect of green tea extract and tamoxifen on mouse mammary preneoplastic lesions
• Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha
• Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice
• Vitamin E Increases Biomarkers of Estrogen Stimulation When Taken With Tamoxifen
• Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue
• Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor--dependent and estrogen receptor--independent mechanisms
• The phytochemical lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors
• Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism
• Association between Alcohol Intake and Serum Sex Hormones and Peptides Differs by Tamoxifen Use in Breast Cancer Survivors

      Per maggiori informazioni sul tumore della mammella  www.senologia.eu